{
  "id": "resp_0c4c2cee152e2bc600693c89d116948193a6997312b750f17a",
  "object": "response",
  "created_at": 1765575121,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0c4c2cee152e2bc600693c89d16988819382cadadbac5adf3f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0c4c2cee152e2bc600693c89f8b29c81939994470394aa0357",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "FDA label Lynparza olaparib PARP inhibitor"
      }
    },
    {
      "id": "rs_0c4c2cee152e2bc600693c89fa3e94819398eae2e0d56c4df2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0c4c2cee152e2bc600693c89fe7a108193a8a476d505c9a33b",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration"
      }
    },
    {
      "id": "rs_0c4c2cee152e2bc600693c89ff12a08193b608018723d7c8cb",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0c4c2cee152e2bc600693c89ff7b608193ab8f1bbb3c877f25",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf"
      }
    },
    {
      "id": "rs_0c4c2cee152e2bc600693c8a005d6c8193971427363ff9e80b",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0c4c2cee152e2bc600693c8a27b5108193a80532e65087bf2b",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": false,\n  \"assets\": [],\n  \"rejected_reason\": \"Olaparib is not a CDK12 or CDK12/13 inhibitor/degrader; it is a poly(ADP-ribose) polymerase (PARP) inhibitor (target mismatch vs. the query). Evidence: FDA Lynparza (olaparib) label states it is a PARP inhibitor: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 17331,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 4332,
    "output_tokens_details": {
      "reasoning_tokens": 4213
    },
    "total_tokens": 21663
  },
  "user": null,
  "metadata": {}
}